Literature DB >> 3904867

Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment.

J H Antin, D Ginsburg, B R Smith, D G Nathan, S H Orkin, J M Rappeport.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) involves the proliferation of an abnormal and possibly premalignant hematopoietic stem cell. Successful treatment of PNH by marrow grafting requires that the PNH clone be eradicated by the pretransplant conditioning regimen. Four patients with PNH-associated marrow aplasia were transplanted with marrow from their HLA-matched, MLR-nonreactive siblings. Three patients were conditioned with cyclophosphamide, procarbazine, and antithymocyte serum (CTX/PCZ/ATS), and one was conditioned with busulfan/CTX/PCZ/ATS. Persistent complete engraftment of myeloid, lymphoid, and erythroid cell lines was demonstrated in all four patients by DNA sequence polymorphism analysis or cytogenetics, and RBC typing. There was no recurrence of the abnormal clone of cells for up to five years after transplantation despite the use of a conditioning regimen in three of them, which is not usually associated with permanent marrow aplasia. Bone marrow transplantation is a curative therapy in patients whose illness is severe enough to warrant the risk.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3904867

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Stem cell transplantation for paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

Review 3.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

4.  Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

Authors:  Jeremy Pantin; Xin Tian; Nancy Geller; Catalina Ramos; Lisa Cook; Elena Cho; Phillip Scheinberg; Sumithira Vasu; Hahn Khuu; David Stroncek; John Barrett; Neal S Young; Theresa Donohue; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-17       Impact factor: 5.742

Review 5.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

Review 6.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 7.  Paroxysmal nocturnal hemoglobinuria from bench to bedside.

Authors:  Jeffrey J Pu; Robert A Brodsky
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

8.  Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome.

Authors:  H Tanaka; N Imamura; N Oguma; T Shintani; K Tanaka; H Hyodo; K Oda; A Kimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 9.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

10.  How I treat paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.